Altria Group, Inc. reports developments across its U.S. tobacco and smoke-free nicotine portfolio. Its operating companies include Philip Morris USA in cigarettes, John Middleton in cigars, U.S. Smokeless Tobacco Company in moist smokeless tobacco, Helix Innovations in oral nicotine pouches and NJOY in e-vapor products. News commonly covers quarterly results and guidance, dividends and share repurchases, product and retail updates for on! and on! PLUS nicotine pouches, and FDA marketing authorizations for smoke-free products.
Company updates also address shareholder meetings, board and executive governance, responsibility priorities such as underage-use prevention and environmental impact, and Altria's stated strategy of moving adult nicotine consumers toward smoke-free alternatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Altria Group, Inc. (NYSE: MO) reported first-quarter 2023 results, demonstrating a 5.4% increase in adjusted diluted EPS to $1.18, while net revenues decreased by 2.9% to $5,719 million. The company reaffirmed its full-year adjusted diluted EPS guidance of $4.98 to $5.13, reflecting a growth rate of 3% to 6% from 2022. Despite facing challenges from high inflation impacting adult tobacco consumer behaviors and a decline in cigarette volumes, Altria maintained brand loyalty in its tobacco segment. Additionally, Altria announced plans to complete a $2.75 billion acquisition of NJOY and has retired $1.3 billion of debt in early 2023.
The company also highlighted its commitment to sustainability with goals such as achieving 100% renewable electricity by 2030.
A recent survey from Altria (NYSE: MO) indicates strong support for tobacco harm reduction strategies among American adults. Approximately 66% of participants advocate for the FDA to prioritize harm reduction instead of prohibition, believing it essential for adult smokers to access smoke-free alternatives. Notably, 90% of respondents feel the FDA should inform consumers about the risks of different tobacco products, and 84% believe prohibition would spawn illicit markets, potentially compromising public health. The survey found support among primary care physicians and policy professionals, with 89% and 78% respectively backing harm reduction as a more effective regulatory strategy. Overall, the findings stress the public’s desire for a regulated, informed approach to tobacco usage, which could significantly impact Altria's future business strategy.